Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2169

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2169
---
 products for which we receive regulatory approval. We also expect to incur
additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in
order to maintain our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we may be forced to
delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.

71

Our
actual capital requirements may vary significantly from what we expect, and we will in any event require additional capital in order
to complete clinical development of any of our current programs. Our monthly spending levels will vary based on new and ongoing development
and corporate activities. Because the length of time and the activities associated with development of our product candidates are highly
uncertain, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities. Our
future funding requirements, immediate, near and long-term, will depend on many factors, including, but not limited to:

    ●
    the
    initiation, progress, timing, costs and results of discovery, laboratory testing, manufacturing, preclinical studies and clinical
    trials for our current and future product candidates, including whether and when to advance our diverse portfolio of product candidates;

    ●
    the
    development requirements of other product candidates that we may pursue;

    ●
    the
    clinical development plans we establish for our product candidates;

    ●
    the
    timelines of our clinical trials and the overall costs to finish the clinical trials;

    ●
    the
    impact on timelines and costs due to unforeseen events;

    ●
    the
    number and characteristics of product candidates that we develop;

    ●
    the
    outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, and other
    comparable foreign regulatory authorities;

    ●
    the
    cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;

    ●
    the
    cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our
    product candidates;

    ●
    the
    extent to which we enter into additional collaboration agreements with regard to product discovery or acquire or in-license products
    or technologies;

    ●
    the
    effect of competing technological and market developments;

    ●
    the
    cost and timing of completion of commercial-scale outsourced manufacturing activities